Abstract
noni, the juice of the fruit from the Morinda citrifolia plant, has been used for centuries as a medicinal agent. We tested the effects of noni juice in a three-dimensional fibrin clot matrix model using human placental vein and human breast tumor explants as sources for angiogenic vessel development. Noni in concentrations of 5% (vol/vol) or greater was highly effective in inhibiting the initiation of new vessel sprouts from placental vein explants, compared with initiation in control explants in media supplemented with an equivalent amount of saline. These concentrations of noni were also effective in reducing the growth rate and proliferation of newly developing capillary sprouts. When used at a concentration of 10% in growth media, noni was able to induce vessel degeneration and apoptosis in wells with established capillary networks within a few days of its application. We also found that 10% noni juice in media was an effective inhibitor of capillary initiation in explants from human breast tumors. In tumor explants which did show capillary sprouting, the vessels rapidly degenerated (2–3 days) in those exposed to media supplemented with 10% noni.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Folkman J. Tumor angiogenesis: Theraputic implications. N Engl J Med 1971; 285: 1182–6.
Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86(3): 353–64.
Clauss M, Sunderkotter C, Sveinbjornsson B et al. A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability. Blood 2001; 97(5): 1321–9.
Gasparini G. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs 1999; 58: 17–38.
Li WW. Tumor Angiogenesis: Molecular pathology, theraputic targeting, and imaging. Acta Radiol 2000; 7: 800–11.
Rosen L. Antiangiogenic strategies and agents in clinical trials. Oncologist 2000; 5(Suppl 1): 20–7.
Denekamp J. Vascular endothelium as the vulnerable element in tumors. Acta Radiol Oncol 1994; 23: 217–25.
Rosen LS. Angiogenesis inhibition in solid tumors. Cancer J 2001; 7(Suppl 3): S120–S8.
Hill S, Lonergan S, Denekamp J, Chaplin D. Vinca alkaloids: Anti-vascular effects in a murine tumor. Eur J Cancer 1993; 29: 1320–4.
Baguley B, Holdway K, Thomsen L et al. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine. Evidence for a vascular mechanism. Eur J Cancer 1991; 27: 482–7.
Bibby M, Double J, Loadman P, Duke C. Reduction of tumor blood flow by flavone acetic acid: A possible mechanism of its antitumor action. J Natl Cancer Inst 1989; 81: 216–20.
Chaplin D, Pettit G, Hill S. Anti-vascular approaches to solid tumor therapy: Evaluation of combrestatin A4 phosphate. Anticancer Res 1999; 19: 189–96.
Abbot IA, Shimazu C. The geographical origin of the plants most commonly used for medicine by Hawaiians. J Ethnopharm 1985; 14: 213–22.
Krauss B. Plants in Hawaiian Culture. Honolulu, Hawaii: University of Hawaii Press 1993.
Hirazumi A. An immunomodulatory polysaccharide rich substance from the fruit juice of Morinda citrifolia (noni) with antitumor activity. Phytother Res 1999; 13: 380–7.
Hiramatsu T, Imoto M, Koyano T, Umezawa K. Induction of normal phenotypes in ras-transformed cells by damnacanthal from Morinda citrifolia. Cancer Lett 1993; 73: 161–6.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hornick, C.A., Myers, A., Sadowska-Krowicka, H. et al. Inhibition of angiogenic initiation and disruption of newly established human vascular networks by juice from Morinda citrifolia (noni). Angiogenesis 6, 143–149 (2003). https://doi.org/10.1023/B:AGEN.0000011800.04507.4b
Issue Date:
DOI: https://doi.org/10.1023/B:AGEN.0000011800.04507.4b